As a biologist, it is clear to me that the greatest tool an athlete or any human being can have is his mind. But despite this for me everything and when I say everything I mean everything is emotional. 20 years ago I had no ideas about emotions despite being at Harvard Medical School doing my post-doal studies at the children hospital in Boston.It was precisely 20 years ago in 2004 when I decided after a series of very stressful work episodes to become my own guinea pig. A fact that I continue to do to this ...

You pick up the phone when your best friend, partner, or child is calling and you know from the moment they say hello how they're feeling. We all know there's a big difference between hey and hi. You know this person so well that the most subtle tone change says it all.And you know exactly what kind of conversation you're about to have. But let me ask you, do you know your own body this well. I want you to imagine your physical being on the other line.Our bodies are constantly calling us in the form of feel ...

[Applause] [Music] [Applause] Hello everyone. What if everyone was born without hair. Now, before you start thinking, what is she talking about.Just hear me out. About a year ago, me and my brother were sitting in our living room asking each other different whatif questions when we landed on the one about hair. We started to argue with each other if we would cherish and worship people born with hair in the society without it or would we shun them and see them as outcasts.In life, our modern world is drownin ...

The presentation will include data from over 90 patients in both the plaque brachytherapy and enucleation-eligible cohorts Darovasertib has received U.S. FDA Breakthrough Therapy Designation for use in neoadjuvant uveal melanoma for subjects requiring enucleation Initiated a multi-site, global randomized Phase 3 neoadjuvant registrational trial in primary uveal melanoma (OptimUM-10) in Q3 2025SOUTH SAN FRANCISCO, Calif., July 24, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading preci ...

Core Viewpoint - Akeso, Inc. has initiated a pivotal Phase III clinical trial for ivonescimab, a first-in-class PD-1/VEGF bispecific antibody, aimed at treating metastatic pancreatic cancer in combination with chemotherapy and potentially ligufalimab [1][3] Industry Overview - Pancreatic cancer is a highly aggressive malignancy with a rising global incidence, leading to approximately 511,000 new cases and 467,000 deaths in 2022. The overall survival rate remains alarmingly low, with current first-line treatments primarily consisting of chemotherapy showing limited success, resulting in a median overall survival of less than one year [4] - The unique immune evasion mechanisms and immunosuppressive tumor microenvironment of pancreatic cancer have made it resistant to existing therapies, with no immunotherapy approved for first-line treatment to date [2][4] Company Overview - Akeso is a leading biopharmaceutical company focused on developing innovative biological medicines, with a robust pipeline of over 50 assets in various therapeutic areas, including cancer. The company employs an integrated R&D innovation system and has developed a comprehensive drug development platform [10] - The ongoing Phase III trial for ivonescimab is part of Akeso's strategy to address significant unmet clinical needs in oncology, particularly for metastatic pancreatic cancer [3][10]

[Applause] Let me let me tell you a story. I'm Esther and when I was in middle school, I was really insecure about what I looked like and even how I talked or acted. I hated my nose and felt like I had to stop eating in order for my body to look a certain way.Why not for myself. It was to fit in with others and look like everyone else or the pretty popular girls or like the pretty popular girls. I would This was also around the time that I got my first phone and downloaded that social media app, Instagram.I ...

Core Insights - Akari Therapeutics is advancing its research on PH1, a novel spliceosome modulator that induces cancer cell death and activates the immune system to combat cancer [1][4] - The company is focused on developing antibody drug conjugates (ADCs) utilizing the PH1 payload, with ongoing preclinical studies expected to yield new data by year-end [1][3] Company Overview - Akari Therapeutics specializes in oncology biotechnology, developing innovative ADCs with a unique mechanism of action through the PH1 payload, which disrupts RNA splicing [4] - The lead candidate, AKTX-101, targets the Trop2 receptor and has shown significant activity and prolonged survival in preclinical studies compared to traditional ADCs [4] Research and Development - Ongoing research aims to explore the effects of PH1 on key oncogenic drivers such as KRAS, BRAF, and FGFR3, with preliminary data anticipated soon [2][3] - The PH1 payload has demonstrated the ability to induce cytotoxicity in cancer cells and activate immune responses, potentially leading to improved therapeutic outcomes [2][6]

WALTHAM, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today announced the addition of Akiko Iwasaki, Ph.D., Professor of Immunobiology at Yale School of Medicine, to the SPEAR (Spike Protein Elimination and Recovery) Study Group. The SPEAR Study Group was launched earlier this month to focus on the biology and clinical disease or injury associated with persistent presence of spike antigen from SARS-CoV-2 virus or COVID-19 vaccines. Dr. Iwasaki is internationally recognized for her ...

Core Insights - Samsung Biologics reported strong financial results for Q2 2025, with consolidated revenue of KRW 1,289.9 billion and operating profit of KRW 475.6 billion, reflecting a year-over-year increase in revenue of 11.5% and operating profit of 9.5% [3][4][9] Financial Performance - The standalone revenue for Samsung Biologics in Q2 2025 was KRW 1,014.2 billion, with an operating profit of KRW 477.0 billion, driven by full utilization of Plants 1 through 3 and the ramp-up of Plant 4 [3][4] - In the first half of 2025, standalone revenue exceeded KRW 2 trillion, with sales contract volume reaching USD 2.4 billion, bringing the cumulative value to USD 18.7 billion [4] Business Developments - The company has fully operationalized Plant 5, adding 180 kL of capacity to enhance manufacturing capabilities and meet client needs [5] - Samsung Biologics launched Samsung Organoids, a new research service utilizing patient-derived organoids for drug discovery, enabling precision screening and multi-modal insights [6] - Plans to spin off Samsung Bioepis were announced, allowing the company to focus on its core CDMO capabilities and enhance customer satisfaction [7] Sustainability Initiatives - Samsung Biologics released its 2025 ESG report, highlighting a 24% reduction in greenhouse gas emissions in 2024 and an increase in renewable energy use to 29% of total electricity consumption [8] - The company signed a solar Power Purchase Agreement to support its energy transition and is involved in initiatives to decarbonize healthcare supply chains [10] Industry Position - Samsung Biologics operates with a combined biomanufacturing capacity of 784 kL across five plants, offering end-to-end integrated services from late discovery to commercial manufacturing [11] - The company leverages advanced technologies to advance diverse modalities, including multispecific antibodies and mRNA therapeutics, positioning itself as a leader in the CDMO sector [11][12]

Clinical efficacy and safety data will be presented from over 70 small-cell lung cancer (SCLC) patients in Hengrui's ongoing, multi-site, open label Phase 1 trial Data will include patients from the dose escalation and at multiple expansion doses U.S. Phase 1 trial of IDE849 in SCLC patients initiated in 3Q 2025JIANGSU, China and SOUTH SAN FRANCISCO, Calif., July 22, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, and Jiangsu Hengrui Pharmaceutic ...